Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018081318 - PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE

Publication Number WO/2018/081318
Publication Date 03.05.2018
International Application No. PCT/US2017/058370
International Filing Date 25.10.2017
IPC
A61K 39/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
CPC
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2770/20022
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/20034
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applicants
  • THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US]/[US]
  • TRUSTEES OF DARTMOUTH COLLEGE [US]/[US]
  • THE SCRIPPS RESEARCH INSTITUTE [US]/[US]
Inventors
  • GRAHAM, Barney
  • MCLELLAN, Jason
  • WARD, Andrew
  • COTTRELL, Christopher
  • JOYCE, Michael, Gordon
  • KANEKIYO, Masaru
  • WANG, Nianshuang
  • PALLESEN, Jesper
  • YASSINE, Hadi
  • TURNER, Hannah
  • KIRCHDOERFER, Robert
  • CORBETT, Kizzmekia
Agents
  • SCOTT, Gregory, K.
Priority Data
62/412,70325.10.2016US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE
(FR) PROTÉINES DE SPICULE DE CORONAVIRUS DE PRÉFUSION ET UTILISATION ASSOCIÉE
Abstract
(EN) Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
(FR) L'invention concerne des trimères d'ectodomaine S de coronavirus stabilisés dans une conformation de préfusion, des molécules d'acide nucléique et des vecteurs codant pour ces protéines, ainsi que des méthodes d'utilisation et des procédés de production associés. Dans plusieurs modes de réalisation, les trimères d'ectodomaine S de coronavirus et/ou les molécules d'acide nucléique peuvent servir à générer une réaction immunitaire contre un coronavirus chez un patient. Dans d'autres modes de réalisation, une quantité thérapeutiquement efficace des trimères d'ectodomaine S de coronavirus et/ou des molécules d'acide nucléique peut être administrée à un patient dans le cadre d'une méthode de traitement ou de prévention d'une infection à coronavirus.
Related patent documents
Latest bibliographic data on file with the International Bureau